CARMAT CARMAT Stock Deutsche Boerse AG
Equities
CXT
FR0010907956
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
After market 03:59:05 pm | |||
| 2.835 EUR | -5.66% |
|
2.825 | -0.35% |
| May. 21 | CARMAT : Invest Securities remains Buy, lowers its target | CF |
| May. 17 | Oddo BHF Cuts Carmat PT, Affirms Neutral Rating | MT |
| Sales 2024 * | 20.98M 22.53M | Sales 2025 * | 43.62M 46.83M | Capitalization | 103M 110M |
|---|---|---|---|---|---|
| Net income 2024 * | -39M -41.87M | Net income 2025 * | -30M -32.21M | EV / Sales 2024 * | 7.96 x |
| Net Debt 2024 * | 64.27M 69M | Net Debt 2025 * | 106M 113M | EV / Sales 2025 * | 4.77 x |
| P/E ratio 2024 * |
-2.12
x | P/E ratio 2025 * |
-2.95
x | Employees | 182 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -5.99% | ||
| 1 week | -5.81% | ||
| Current month | -7.95% | ||
| 1 month | -32.26% | ||
| 3 months | -29.65% | ||
| 6 months | -57.81% | ||
| Current year | -58.12% |
1 week
2.84
3.05
1 month
2.844.31
Current year
2.847.50
1 year
2.849.42
3 years
2.8430.80
5 years
2.8435.85
10 years
2.8491.59
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | 53 | 16-08-31 |
| Director of Finance/CFO | - | 18-12-11 | |
Marc Grimmé
CTO | Chief Tech/Sci/R&D Officer | - | 08-06-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Director/Board Member | 61 | 21-05-06 |
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 2.835 | -5.66% |
| 24-06-12 | 3.005 | +4.16% |
| 24-06-11 | 2.885 | -1.70% |
| 24-06-10 | 2.935 | -2.33% |
| 24-06-07 | 3.005 | +0.50% |
Delayed Quote Deutsche Boerse AG, June 13, 2024 at 11:20 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.98
EUR
Average target price
12.32
EUR
Spread / Average Target
+313.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.55% | 132B | |
| -6.26% | 11.37B | |
| -10.14% | 7.97B | |
| +42.95% | 5.71B | |
| -17.77% | 4.98B | |
| +8.21% | 3.42B | |
| -19.83% | 2.48B | |
| -13.82% | 1.99B | |
| -15.84% | 1.86B |
- Stock Market
- Equities
- ALCAR Stock
- CXT Stock
